The Journal of Practical Medicine ›› 2025, Vol. 41 ›› Issue (6): 916-920.doi: 10.3969/j.issn.1006-5725.2025.06.022

• Reviews • Previous Articles    

Research progress of hybrid coronary revascularization in treating coronary atherosclerotic heart disease

Xiaoyu ZHANG1,Yuanyuan PAN2,Minghuan FU2,Yun LIN2,Yiran CHEN3,Yu. PENG2()   

  1. School of Medicine of University of Electronic Science and Technology of China,Chengdu 610054,Sichuan,China
  • Received:2025-02-07 Online:2025-03-25 Published:2025-03-31
  • Contact: Yu. PENG E-mail:369837306@qq.com

Abstract:

The incidence rate of coronary atherosclerotic heart disease (commonly referred to as coronary heart disease) remains high in China. In clinical practice, drug therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG) are commonly employed. For patients with multi?vessel coronary artery stenosis, minimally invasive interventional therapy is often the preferred option. However, for those with multi?vessel disease complicated by comorbidities, CABG is generally recommended. Despite its advantages, PCI carries risks such as vascular restenosis, thrombosis, and other adverse events. Consequently, hybrid coronary revascularization (HCR) has emerged as an alternative approach. This paper provides an overview of coronary heart disease and reviews the advantages, applications, and patient selection criteria for HCR.

Key words: hybrid coronary revascularization, coronary atherosclerotic heart disease, percutaneous coronary intervention, coronary artery bypass grafting, progress

CLC Number: